Abbott (NYSE:ABT) announces the FDA nod for its Gallant implantable cardioverter defibrillator (ICD) and cardiac resynchronization therapy defibrillator (CRT-D) devices.
The company says new features include a patient-preferred design without compromising battery life and MRI compatibility and a smartphone app for improved remote monitoring.
The Gallant system was CE Mark’d in February.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.